Natesto is the first and only FDA approved intranasal testosterone replacement therapy. Natesto is an androgen indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism.
ProstaScint is an FDA-approved biologic indicated for the detection of prostate cancer. It is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. ProstaScint consists of a novel monoclonal antibody that, when conjugated to a linker-chelator and radiolabeled, binds distinctly to Prostate Specific Membrane Antigen (PSMA).